Rome, 3 Nov. (AdnKronos Salute) – A collaboration agreement between the Italian Medicines Agency and the Competition Authority, to avoid unfair commercial practices by pharmaceutical companies to the detriment of the NHS and patients and speculation on drug prices. This was announced by Health Minister Beatrice Lorenzin, responding to Question Time in the Chamber, to a question on the initiatives to be implemented against possible speculation on the prices of medicines after the case of the Aspen company, fined by the Antitrust.
"Precisely in the light of this case - says the minister - I gave indications to the AIFA top management for the stipulation of an interinstitutional agreement that formalizes and consolidates the fruitful collaboration between the two entities in the pharmaceutical sector. This collaboration will make public intervention in determining the price of medicines even more incisive”.
Not only. The Stability Law, in addition to allocating dedicated funds for innovative oncological drugs, "provides for a more effective attribution of the innovativeness requirement of medicinal products, including oncological ones, with new procedures to ascertain what is innovative, how long innovation lasts and how it should be managed in such a delicate sector”, concludes the minister.
Source Focus.it – 03/11/2016
Related news: The uniform prices set in Germany for prescription medicines are contrary to EU law
Antitrust: 5 million fine to the pharmaceutical company Aspen
